Government policy is hurting creativity say Nobel Laureates
This article was originally published in Scrip
A clutch of Nobel Laureates believe that directing government research funding to projects that are expected to produce economic benefits is misguided. The UK's switch in the 1970s to more targeted research funding, for example, correlated with a decline 20 years later in the number of prizes that the country won. The big advances in science, and resultant economic benefit, come from discoveries that cannot be predicted, claim Sir Tim Hunt, Sir Aaron Klug and others, in a letter to the Financial Times (June 24th, p 14).
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Europe’s strengths in the biotech space include world-class science, but the continent needs to build on its strengths in order to deliver on the promise of a coming “golden age” of biotech, says a recent report.
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.